320 related articles for article (PubMed ID: 21112660)
21. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
22. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
[TBL] [Abstract][Full Text] [Related]
23. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
24. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
26. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
27. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
[TBL] [Abstract][Full Text] [Related]
29. Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.
Akkız H; Akgöllü E; Bekar A; Yıldırım S; Sandıkçı M; Ülger Y; Yalınbaş Kaya B; Kuran S; Üsküdar O
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):711-7. PubMed ID: 25857516
[TBL] [Abstract][Full Text] [Related]
30. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
31. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
32. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Sugimoto K; Kim SK; Tanaka Y; Hatae T; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Kudo M
Dig Dis; 2013; 31(5-6):426-33. PubMed ID: 24281016
[TBL] [Abstract][Full Text] [Related]
33. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
[TBL] [Abstract][Full Text] [Related]
34. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
35. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Craig JC; Sharafi H
J Clin Lab Anal; 2017 Jul; 31(4):. PubMed ID: 27735085
[TBL] [Abstract][Full Text] [Related]
36. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
[TBL] [Abstract][Full Text] [Related]
37. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.
Ochi H; Maekawa T; Abe H; Hayashida Y; Nakano R; Imamura M; Hiraga N; Kawakami Y; Aimitsu S; Kao JH; Kubo M; Tsunoda T; Kumada H; Nakamura Y; Hayes CN; Chayama K
J Gen Virol; 2011 May; 92(Pt 5):1071-1081. PubMed ID: 21228123
[TBL] [Abstract][Full Text] [Related]
38. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Bochud PY; Bibert S; Negro F; Haagmans B; Soulier A; Ferrari C; Missale G; Zeuzem S; Pawlotsky JM; Schalm S; Hellstrand K; Neumann AU; Lagging M
J Hepatol; 2011 Nov; 55(5):980-8. PubMed ID: 21354446
[TBL] [Abstract][Full Text] [Related]
39. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
